October 28, 2016 2:05 AM ET


Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic therapeutics for the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome, as well as in Phase IIb clinical trial for the treatment of hyperphosphatemia or elevated serum phosphorus levels in patients with end-stage renal disease. The company is also developing RDX022, an oral, non-absorbed potassium-binder for the treatment of hyperkalemia or elevated serum potassium. Its drug candidates in earlier stages of research and development include RDX0...

34175 Ardenwood Boulevard

Suite 200

Fremont, CA 94555

United States

Founded in 2007

61 Employees





Key Executives for Ardelyx, Inc.

Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $470.0K
Chief Financial Officer and Principal Accounting Officer
Age: 48
Total Annual Compensation: $320.0K
Senior Vice President and General Counsel
Age: 52
Total Annual Compensation: $300.0K
Chief Scientific Officer and Executive Vice President
Age: 47
Total Annual Compensation: $132.1K
Compensation as of Fiscal Year 2015.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Appoints Reginald Seeto as Chief Operating Officer

Ardelyx, Inc. announced that Reginald Seeto has joined the company in the newly created position of chief operating officer. Dr. Seeto brings over a decade of pharmaceutical industry experience in corporate development, strategic operations and global marketing to Ardelyx. His appointment is effective immediately. Prior to joining the company, he spent eight years in roles of increasing responsibility at AstraZeneca and MedImmune, most recently serving as vice president, head of partnering and strategy for AstraZeneca. Earlier, he served as company president of AstraZeneca Thailand and before that, as executive vice president of corporate development and strategy for MedImmune.

Ardelyx, Inc. Presents at Annual Sofinnova Japan Biopharma Partnering Conference, Oct-25-2016 03:25 PM

Ardelyx, Inc. Presents at Annual Sofinnova Japan Biopharma Partnering Conference, Oct-25-2016 03:25 PM. Venue: Conrad Hotel, 1-9-1, Higashi-Shinbashi, Minato-Ku, Tokyo, 105 7337, Japan.

Ardelyx, Inc.(NasdaqGM:ARDX) added to S&P Global BMI Index

Ardelyx, Inc.(NasdaqGM:ARDX) added to S&P Global BMI Index

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
July 14, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.